Pretransplant malignancy in pediatrics is not a risk factor for renal graft failure.
malignancy
pediatric kidney transplant
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
25
11
2023
received:
25
07
2023
accepted:
05
12
2023
medline:
6
2
2024
pubmed:
6
2
2024
entrez:
6
2
2024
Statut:
ppublish
Résumé
In adults, pretransplant malignancy (PTM) negatively impacts patient survival due to immunosuppression regimens influencing post-transplantation tumor growth. Few reports investigate the outcomes of pediatric kidney transplantation with PTM. We compare transplant outcomes for pediatric patients with PTM to matched controls, including cancer types extending beyond Wilms tumor. The United Network of Organ Sharing Database was queried to identify pediatric transplant recipients with histories of PTM. All PTM patients were matched to non-PTM patients, at a 1:1 ratio, with 0.001 match tolerance. Matching variables included transplant year, recipient age, recipient gender, recipient race, donor type, and prior transplant. Death-censored graft and patient survival were analyzed. All statistics were reported with 95% confidence intervals (CI). After propensity matching, 285 PTM and 285 non-PTM patients were identified, with transplant dates from 1990 to 2020. Median Kidney Donor Profile Index values were comparable between cohorts, 17% and 12%, respectively (p = .065). Kaplan-Meier analysis revealed that PTM patients did not have a significantly different rate of death-censored graft failure, compared to the non-PTM group [HR 0.76; 95% CI (0.54-1.1)]. There was also no difference in the overall survival between the two groups of patients [HR 1.1; 95% CI (0.66-2.0)]. A history of pediatric malignancy has minimal independent effect on their post-transplant survival. Additionally, pediatric patients with PTM demonstrated equivalent rates of graft survival. Thus, in contrast to adults, renal failure in children with history of pediatric malignancies should not be considered a complicating factor for renal transplantation.
Sections du résumé
BACKGROUND
BACKGROUND
In adults, pretransplant malignancy (PTM) negatively impacts patient survival due to immunosuppression regimens influencing post-transplantation tumor growth. Few reports investigate the outcomes of pediatric kidney transplantation with PTM. We compare transplant outcomes for pediatric patients with PTM to matched controls, including cancer types extending beyond Wilms tumor.
METHODS
METHODS
The United Network of Organ Sharing Database was queried to identify pediatric transplant recipients with histories of PTM. All PTM patients were matched to non-PTM patients, at a 1:1 ratio, with 0.001 match tolerance. Matching variables included transplant year, recipient age, recipient gender, recipient race, donor type, and prior transplant. Death-censored graft and patient survival were analyzed. All statistics were reported with 95% confidence intervals (CI).
RESULTS
RESULTS
After propensity matching, 285 PTM and 285 non-PTM patients were identified, with transplant dates from 1990 to 2020. Median Kidney Donor Profile Index values were comparable between cohorts, 17% and 12%, respectively (p = .065). Kaplan-Meier analysis revealed that PTM patients did not have a significantly different rate of death-censored graft failure, compared to the non-PTM group [HR 0.76; 95% CI (0.54-1.1)]. There was also no difference in the overall survival between the two groups of patients [HR 1.1; 95% CI (0.66-2.0)].
CONCLUSION
CONCLUSIONS
A history of pediatric malignancy has minimal independent effect on their post-transplant survival. Additionally, pediatric patients with PTM demonstrated equivalent rates of graft survival. Thus, in contrast to adults, renal failure in children with history of pediatric malignancies should not be considered a complicating factor for renal transplantation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14697Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Lentine KL, Smith JM, Hart A, et al. OPTN/SRTR 2020 annual data report: kidney. Am J Transplant. 2022;22(Suppl 2):21-136. doi:10.1111/ajt.16982
2014 Annual Transplant Report. The Emmes Corporation. 2014. https://naprtcs.org/system/files/2014_Annual_Transplant_Report.pdf. Accessed 21 December 2022.
Wilms' tumor: status report, 1990. By the National Wilms' Tumor Study Committee. J Clin Oncol. 1991;9(5):877-887. doi:10.1200/JCO.1991.9.5.877
Coppes MJ, de Kraker J, van Dijken PJ, et al. Bilateral Wilms' tumor: long-term survival and some epidemiological features. J Clin Oncol. 1989;7(3):310-315. doi:10.1200/JCO.1989.7.3.310
Kist-van Holthe JE, Ho PL, Stablein D, Harmon WE, Baum MA. Outcome of renal transplantation for Wilms' tumor and Denys-Drash syndrome: a report of the north American pediatric renal transplant cooperative study. Pediatr Transplant. 2005;9(3):305-310. doi:10.1111/j.1399-3046.2005.00311.x
Rudin C, Pritchard J, Fernando ON, Duffy PG, Trompeter RS. Renal transplantation in the management of bilateral Wilms' tumour (BWT) and of Denys-Drash syndrome (DDS). Nephrol Dial Transplant. 1998;13(6):1506-1510. doi:10.1093/ndt/13.6.1506
Coppes MJ, Liefers GJ, Higuchi M, Zinn AB, Balfe JW, Williams BR. Inherited WT1 mutation in Denys-Drash syndrome. Cancer Res. 1992;52(21):6125-6128.
Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation. F1000Res. 2019;8:F1000 faculty Rev-194. doi:10.12688/f1000research.16627.1
(ANZDATA) ANZDaTR: 41st annual ANZDATA report. 2018.
Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada. JAMA Oncol. 2016;2(4):463-469. doi:10.1001/jamaoncol.2015.5137
Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM. Management of solid tumours in organ-transplant recipients. Lancet Oncol. 2007;8(10):921-932. doi:10.1016/S1470-2045(07)70315-7
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-1901. doi:10.1001/jama.2011.1592
Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM. Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort. Am J Transplant. 2016;16(2):565-573. doi:10.1111/ajt.13596
Hall EC, Engels EA, Pfeiffer RM, Segev DL. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015;99(5):1051-1057. doi:10.1097/TP.0000000000000449
Chua A, Cramer C, Moudgil A, et al. Kidney transplant practice patterns and outcome benchmarks over 30 years: the 2018 report of the NAPRTCS. Pediatr Transplant. 2019;23(8):e13597. doi:10.1111/petr.13597
Smith JM, Martz K, McDonald RA, Harmon WE. Solid tumors following kidney transplantation in children. Pediatr Transplant. 2013;17(8):726-730. doi:10.1111/petr.12166
Penn I. Renal transplantation for Wilms tumor: report of 20 cases. J Urol. 1979;122(6):793-794. doi:10.1016/s0022-5347(17)56607-0